Desogestrel
Small molecule targets PGR via activation
Regulatory milestones approvals, filings & regulatory actions · 1 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Approved | US (FDA) | DESOGEN | — | 1992-12-10 | fda.gov ↗ |
Trials 25
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT06233084 | Jul → Sep 2024 | — | Bio-innova Co., Ltd | Unknown | No outcome recorded |
| Phase 1 | NCT03353857 | Nov 2017 → Jul 2018 | — | Bayer | Completed | No outcome recorded |
| Phase 1 | NCT01291004 | Jan 2011 → Mar 2012 | — | Teva Branded Pharmaceutical Products R&D, Inc. | Completed | No outcome recorded |
| Phase 23 trials · 1 missed | ||||||
| Phase 2 | NCT01500473 | Feb 2012 → May 2016 | central hypoventilation syndrome, congenital | Children's Hospital Los Angeles | Terminated | No outcome recorded |
| Phase 2 | NCT01310647 | Jun 2011 → Dec 2012 | ovarian disorder | La Fe Health Research Institute | Completed | Missed primary |
| Phase 2 | NCT00151801 | May 2002 → Dec 2008 | multiple sclerosis | S. Andrea Hospital | Unknown | No outcome recorded |
| Phase 2/32 trials | ||||||
| Phase 2/3 | NCT04941833 | Jun 2021 → Jul 2022 | ovarian endometriosis | Department of Medical Services Ministry of Public Health of Thailand | Completed | No outcome recorded |
| Phase 2/3 | NCT01243697 | Apr 2011 → Sep 2013 | central hypoventilation syndrome, congenital | Assistance Publique - Hôpitaux de Paris | Completed | No outcome recorded |
| Phase 35 trials · 1 met primary · 1 missed | ||||||
| Phase 3 | NCT03895099 | Sep 2020 → Oct 2023 | infertility disorder | Centre Hospitalier Intercommunal Creteil | Completed | No outcome recorded |
| Phase 3 | NCT03229057 | Jan 2018 → Jan 2024 | polycystic ovary syndrome | Anuja Dokras | Completed | Missed primary |
| Phase 3 | NCT02103764 | Aug 2013 → Jul 2018 | uterine disorder | Mahidol University | Unknown | Met primary |
| Phase 3 | NCT00624130 | Mar 2004 → Jun 2005 | — | Bayer | Completed | No outcome recorded |
| Phase 3 | NCT00185419 | Nov 2003 → Mar 2006 | — | Bayer | Completed | No outcome recorded |
| Phase 410 trials | ||||||
| Phase 4 | NCT06175832 | Jan 2025 → Dec 2027 expected | — | University Hospital, Ghent | Recruiting | No outcome recorded |
| Phase 4 | NCT06334315 | Oct 2024 → May 2028 expected | — | Yale University | Recruiting | No outcome recorded |
| Phase 4 | NCT05002738 | Sep 2021 → Nov 2022 | — | University of Colorado, Denver | Completed | No outcome recorded |
| Phase 4 | NCT04728659 | Oct 2020 → Jan 2022 | infertility disorder | Casa di Cura Privata Villa Mafalda | Unknown | No outcome recorded |
| Phase 4 | NCT02757287 | May 2016 → Nov 2017 | infertility disorder | Fundacion Dexeus | Withdrawn | No outcome recorded Stop: Business |
| Phase 4 | NCT02367846 | Jan 2015 → Dec 2028 expected | bone development disease | Penn State University | Active not recruiting | No outcome recorded |
| Phase 4 | NCT02367833 | Jan 2015 → Dec 2017 | bone disorder | Penn State University | Completed | No outcome recorded |
| Phase 4 | NCT01438736 | Sep 2011 → Nov 2012 | hemorrhagic disease | VL-Medi Oy | Unknown | No outcome recorded |
| Phase 4 | NCT01482338 | Jun 2011 → Feb 2012 | premenstrual tension | Chulalongkorn University | Completed | No outcome recorded |
| Phase 4 | NCT00826839 | Jan 2009 → Sep 2010 | infertility disorder | Weill Medical College of Cornell University | Withdrawn | No outcome recorded Stop: Enrollment |
| Phase not applicable2 trials · 1 missed | ||||||
| — | NCT05174195 | Aug 2016 → Mar 2018 | progestogen hypersensitivity | University Hospital, Geneva | Terminated | Missed primary Stop: Enrollment |
| — | NCT00204438 | Feb → Dec 2002 | — | University of Saskatchewan | Completed | No outcome recorded |
| Comparator or background therapy20 trials | ||||||
| Phase 1 | NCT07269327 Background | Nov 2025 → Mar 2026 | infertility disorder | Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany | Completed | No outcome recorded |
| Phase 1 | NCT04422028 Comparator | Jan 2020 | — | Laboratorios Andromaco S.A. | Completed | No outcome recorded |
| Phase 2 | NCT06852365 Comparator | Jun 2025 → Apr 2028 expected | metabolic syndrome X, polycystic ovary syndrome | University of Pennsylvania | Recruiting | No outcome recorded |
| Phase 2 | NCT01388491 Background | Oct 2011 → Sep 2012 | vascular hemostatic disease | Teva Branded Pharmaceutical Products R&D, Inc. | Completed | Met primary |
| Phase 2 | NCT01252186 Comparator | Nov 2010 → Dec 2011 | vascular hemostatic disease | Teva Women's Health | Completed | No outcome recorded |
| Phase 2 | NCT00563472 Comparator | Nov 2007 → Aug 2008 | — | Pantarhei Bioscience | Completed | No outcome recorded |
| Phase 3 | NCT01076582 Comparator | Apr 2010 → Oct 2011 | — | Bayer | Completed | No outcome recorded |
| Phase 3 | NCT00946192 Comparator | May 2009 → Feb 2020 | functional hypothalamic amenorrhea | Massachusetts General Hospital | Completed | Met primary |
| Phase 3 | NCT00544882 Comparator | Oct 2007 → Mar 2008 | — | Teva Branded Pharmaceutical Products R&D, Inc. | Completed | No outcome recorded |
| Phase 4 | NCT01638767 Comparator | Jul 2012 → Jul 2014 | infertility disorder | Clinique Ovo | Terminated | No outcome recorded Stop: Enrollment |
| Phase 4 | NCT01588873 Comparator | Apr 2012 → Dec 2018 | — | University of Oulu | Unknown | No outcome recorded |
| Phase 4 | NCT01738724 Comparator | Jan 2012 → Dec 2016 | leiomyoma | University of Sao Paulo | Terminated | No outcome recorded |
| Phase 4 | NCT01384331 Comparator | Jul 2011 → Dec 2012 | menstrual disorder | Family Planning Association New South Wales | Unknown | No outcome recorded |
| Phase 4 | NCT01466673 Comparator | Dec 2008 → Mar 2010 | acne | Janssen-Cilag Ltd.,Thailand | Completed | No outcome recorded |
| — | NCT06304220 Comparator | Jul → Sep 2024 | female infertility | NextFertility | Unknown | No outcome recorded |
| — | NCT06689150 Comparator | Aug 2023 → Aug 2024 | — | Al-Azhar University | Completed | No outcome recorded |
| — | NCT05594186 Comparator | Mar 2019 → Oct 2022 | — | Saudi German Hospital - Madinah | Completed | No outcome recorded |
| — | NCT01559480 Comparator | Jan 2012 → Oct 2014 | endometriosis | Mahidol University | Completed | No outcome recorded |
| — | NCT01087879 Comparator | Oct 2007 → Jan 2011 | — | University of Oulu | Completed | No outcome recorded |
| — | NCT00612508 Comparator | May 2007 → May 2008 | — | Oregon Health and Science University | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2024-09-03 | Organon and Co | Results OG-8276A for Dysmenorrhea Demonstrated Positive Topline Phase 3 Study Results organon.com ↗ |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2024-09-03 | Organon and Co | OG-8276A for Dysmenorrhea Demonstrated Positive Topline Phase 3 Study Results organon.com ↗ |
| 2001-12-07 | Eli Lilly and Company | Barr Granted Summary Judgment in Mircette Patent Challenge lilly.com ↗ |
Evidence & citations 29 cited values
Every value below carries the sentence it was read from. 51 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Desogestrel | “combined oral contraceptive pill (OCP) once daily for 21 days (Desogestrel 150 micrograms/ Ethinylestradiol 30 micrograms, tablets), starting from the first day of menses, then...” NCT05594186 ↗42“The study will utilize a 20mcg OCP but a less androgenic third generation progestin (desogestrel 0.15mg) with potentially lesser impact on lipids and insulin sensitivity.” NCT03229057 ↗ “7 days daily intake of oral capsule containing containing ethinyl oestradiol 30micrograms plus desogestrel 150 micrograms followed by 14 days oral placebo capsules” NCT01384331 ↗ “0.150 mg desogestrel and 0.030 mg ethinyl estradiol tablets, USP. One tablet per day at the same time each day, from the beginning of the menstrual cycle.” NCT01638767 ↗ “Desogestrel Cerazet® 75 mg/day orally from the first day of controlled ovarian hyperstimulation (COH) until the day of trigger with agonist (GnRH-a).” NCT06304220 ↗ “Apri (or generic equivalent - Reclipsen) (30µg/d EE, 150 µg/d desogestrel) is a monophasic dosing regimen of 21 active and 7 placebo pills.” NCT02367833 ↗ “subcutaneous IFN-β-1a 44 mcg tiw plus ethinyl estradiol 20 mcg and desogestrel 150 mcg (Mercilon®, MSD Italia SRL, Rome, Italy)” PMID 27995531 ↗ Feb 2017 “(150µg Desogestrel + 30µg Ethinylestradiol)/day during the luteal phase of the two cycles prior to the ICSI.” NCT01310647 ↗ “Desogestrel/ethinyl estradiol tablets, 0.15 mg/0.03 mg, one tablet by mouth daily for 14 days” NCT00826839 ↗ “desogestrel (DSG) 150 μg/EE 20 μg in a 21/7 regimen (Mercilon®)” PMID 21721590 ↗ 2011 “About 100 women took Desogestrel (Cirazette) tablet every day” NCT06689150 ↗ |
| Known as | Aizea | ChEMBL registry synonym — accepted as the source's own label CHEMBL1533 ↗ |
| Known as | Cerazet | “Desogestrel Cerazet® 75 mg/day orally from the first day of controlled ovarian hyperstimulation (COH) until the day of trigger with agonist (GnRH-a).” NCT06304220 ↗ |
| Known as | Cerazette | “Ovulation inhibition will be performed using Desogestrel (Cerazette, 75 mcg) starting on stimulation day 7 or when the leading follicle will reach 14 mm, whichever comes first.” NCT04728659 ↗3“Desogestrel 75 micrograms POP (Cerazette), Etonogestrel 68 mg implant (Nexplanon)” NCT01438736 ↗ “Desogestrel/ Cerazette” NCT03353857 ↗ |
| Known as | Cerelle | ChEMBL registry synonym — accepted as the source's own label CHEMBL1533 ↗ |
| Known as | DESO | “After a fortuitous observation of two cases of chemosensitivity recovery in women with congenital central hypoventilation syndrome (CCHS) who took desogestrel, we aimed to...” PMID 38336689 ↗ Feb 2024 |
| Known as | Desogestrel component of bekyree | ChEMBL registry synonym — accepted as the source's own label CHEMBL1533 ↗ |
| Known as | Desogestrel component of cyclessa | ChEMBL registry synonym — accepted as the source's own label CHEMBL1533 ↗ |
| Known as | Desogestrel component of desogen | ChEMBL registry synonym — accepted as the source's own label CHEMBL1533 ↗ |
| Known as | Desogestrel component of enskyce | ChEMBL registry synonym — accepted as the source's own label CHEMBL1533 ↗ |
| Known as | Desogestrel component of isibloom | ChEMBL registry synonym — accepted as the source's own label CHEMBL1533 ↗ |
| Known as | Desogestrel component of kariva | ChEMBL registry synonym — accepted as the source's own label CHEMBL1533 ↗ |
| Known as | Desogestrel component of mircette | ChEMBL registry synonym — accepted as the source's own label CHEMBL1533 ↗ |
| Known as | Desogestrel component of ortho-cept | ChEMBL registry synonym — accepted as the source's own label CHEMBL1533 ↗ |
| Known as | Desogestrel component of pimtrea | ChEMBL registry synonym — accepted as the source's own label CHEMBL1533 ↗ |
| Known as | Desogestrel component of velivet | ChEMBL registry synonym — accepted as the source's own label CHEMBL1533 ↗ |
| Known as | Desogestrel component of viorele | ChEMBL registry synonym — accepted as the source's own label CHEMBL1533 ↗ |
| Known as | Desogestrel component of volnea | ChEMBL registry synonym — accepted as the source's own label CHEMBL1533 ↗ |
| Known as | Desomono | ChEMBL registry synonym — accepted as the source's own label CHEMBL1533 ↗ |
| Known as | DSG | “Participants received 21 days of active combination tablets (containing 150 µg desogestrel (DSG)/30 µg EE, followed by no treatment for 7 days in each 28-day cycle for a total...” NCT01252186 ↗8“daily oral 75 µg of Desogestrel (DSG) for 3 months prior to the insertion of etonogestrel-releasing contraceptive implant (ENG-IMPLANT) might help reduce its premature discontinuation.” PMID 36915205 ↗ Mar 2023 “We conducted a 12-sample, 24-hour pharmacokinetic study in healthy reproductive-age females taking a COCP containing 0.15-mg desogestrel (DSG) and 30-μg ethinyl estradiol (EE).” PMID 37331464 ↗ Jun 2023 “There were 104 premenopausal women with AUB-O randomized to desogestrel (DSG 150 µg/d, n = 50) or medroxyprogesterone acetate (MPA 10 mg/d, n = 54) group.” PMID 35102226 ↗ Jan 2022 “a contraceptive oral progesterone only( Desogestrel, DSG) is available for contraception, avoiding the LH surge.” NCT02757287 ↗ “desogestrel (DSG) 150 mcg/ethinyl estradiol (EE) 20 mcg for 21 days” PMID 27328486 ↗ 2016 “desogestrel (DSG) 150 μg/EE 20 μg in a 21/7 regimen (Mercilon®)” PMID 21721590 ↗ 2011 “Ethinylestradiol (EE) and desogestrel (DSG) (Mercilon)” NCT01076582 ↗ “Ethinyl estradiol/Desogestrel (EE/DSG)” NCT01466673 ↗ |
| Known as | Feanolla | ChEMBL registry synonym — accepted as the source's own label CHEMBL1533 ↗ |
| Known as | Mircette | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00544882 ↗ |
| Known as | Nacrez | ChEMBL registry synonym — accepted as the source's own label CHEMBL1533 ↗ |
| Known as | ORG 2969 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1533 ↗ |
| Known as | Zelleta | ChEMBL registry synonym — accepted as the source's own label CHEMBL1533 ↗ |
| Action | Activate | “Progesterone receptor agonist” CHEMBL1533 ↗ |
| Modality | Small molecule | — CHEMBL1533 ↗ |
| Route | Oral | “administered orally” NCT00544882 ↗ |
| Target | PGR | “Progesterone receptor agonist” CHEMBL1533 ↗ |